Risk of lymphoma in patients with atopic dermatitis and the role of topical treatment: A systematic review and meta-analysis

Journal of the American Academy of Dermatology

Volumn 72, Issue 6, 2015, Pages 992-1002

  Legendre, Laureline ^a   Barnetche, Thomas ^b   Mazereeuw Hautier, Juliette ^a   Meyer, Nicolas ^a   Murrell, Dedee ^c   Paul, Carle ^a  

^a UNIVERSITÉ PAUL SABATIER   (France)

^b BORDEAUX UNIVERSITY HOSPITAL   (France)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

atopic dermatitis; lymphoma; neoplasm; pimecrolimus; systematic review; tacrolimus; topical corticosteroids

Indexed keywords

CALCINEURIN INHIBITOR; PIMECROLIMUS; STEROID; TACROLIMUS; CORTICOSTEROID; IMMUNOSUPPRESSIVE AGENT;

ARTICLE; ATOPIC DERMATITIS; CANCER RISK; CUTANEOUS T CELL LYMPHOMA; DISEASE ASSOCIATION; DISEASE SEVERITY; FOLLOW UP; HUMAN; LYMPHOMA; META ANALYSIS; PRIORITY JOURNAL; RISK ASSESSMENT; SKIN LYMPHOMA; SYSTEMATIC REVIEW; TOPICAL TREATMENT; TREATMENT DURATION; AGE DISTRIBUTION; COMORBIDITY; DERMATITIS, ATOPIC; FEMALE; INCIDENCE; LYMPHOMA, T-CELL, CUTANEOUS; MALE; PROGNOSIS; SEVERITY OF ILLNESS INDEX; SEX RATIO; SKIN NEOPLASMS; TOPICAL DRUG ADMINISTRATION;

ADMINISTRATION, TOPICAL; ADRENAL CORTEX HORMONES; AGE DISTRIBUTION; CALCINEURIN INHIBITORS; COMORBIDITY; DERMATITIS, ATOPIC; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; LYMPHOMA, T-CELL, CUTANEOUS; MALE; PROGNOSIS; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SEX DISTRIBUTION; SKIN NEOPLASMS; TACROLIMUS;

EID: 84929654103     PISSN: 01909622     EISSN: 10976787     Source Type: Journal    
DOI: 10.1016/j.jaad.2015.02.1116     Document Type: Article

References (40)

1. H.C. Williams Epidemiology of atopic dermatitis Clin Exp Dermatol 25 2000 522 529
2. L.F. Eichenfield, W.L. Tom, and S.L. Chamlin Guidelines of care for the management of atopic dermatitis: section 1. Diagnosis and assessment of atopic dermatitis J Am Acad Dermatol 70 2014 338 351
3. F. Mougel, S. Dalle, B. Balme, R. Houot, and L. Thomas Aggressive CD30 large cell lymphoma after cyclosporine given for putative atopic dermatitis Dermatology 213 2006 239 241
4. N. Meyer, J. Mazereeuw-Hautier, F. Launay, L. Lamant, and C. Paul Cutaneous T cell lymphoma complicating severe atopic dermatitis. Is making a diagnosis the main challenge? Dermatology 218 2009 168 171
5. E.C. Siegfried, J.C. Jaworski, and A.A. Hebert Topical calcineurin inhibitors and lymphoma risk: evidence update with implications for daily practice Am J Clin Dermatol 14 2013 163 178
6. Ottawa Hospital Research Institute website. Newcastle-Ottawa quality assessment scale case control studies. Available at: http://www.ohri.ca/programs/clinical-epidemiology/nosgen.pdf. Accessed September 8, 2014.
7. E. von Elm, D.G. Altman, and M. Egger The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies Ann Intern Med 147 2007 573 577
8. J.P.T. Higgins, and S.G. Thompson Quantifying heterogeneity in a meta-analysis Stat Med 21 2002 1539 1558
9. A. Arana, C.E. Wentworth, C. Fernández-Vidaurre, R.G. Schlienger, E. Conde, and F.M. Arellano Incidence of cancer in the general population and in patients with or without atopic dermatitis in the U.K Br J Dermatol 163 2010 1036 1043
10. F.M. Arellano, C.E. Wentworth, A. Arana, C. Fernández, and C.F. Paul Risk of lymphoma following exposure to calcineurin inhibitors and topical steroids in patients with atopic dermatitis J Invest Dermatol 127 2007 808 816
11. F.M. Arellano, A. Arana, C.E. Wentworth, C. Fernández-Vidaurre, R.G. Schlienger, and E. Conde Lymphoma among patients with atopic dermatitis and/or treated with topical immunosuppressants in the United Kingdom J Allergy Clin Immunol 123 2009 1111 1116 116.e1-e13
12. L. Bernstein, and R.K. Ross Prior medication use and health history as risk factors for non-Hodgkin's lymphoma: preliminary results from a case-control study in Los Angeles County Cancer Res 52 19 suppl 1992 5510s 5515s
13. R.A. Cartwright, P.A. McKinney, and C. O'Brien Non-Hodgkin's lymphoma: case control epidemiological study in Yorkshire Leuk Res 12 1988 81 88
14. W. Cozen, J.R. Cerhan, and O. Martinez-Maza The effect of atopy, childhood crowding, and other immune-related factors on non-Hodgkin lymphoma risk Cancer Causes Control 18 2007 821 831
15. P. Fabbro-Peray, J.P. Daures, and J.F. Rossi Environmental risk factors for non-Hodgkin's lymphoma: a population-based case-control study in Languedoc-Roussillon, France Cancer Causes Control 12 2001 201 212
16. A.E. Grulich, C.M. Vajdic, and J.M. Kaldor Birth order, atopy, and risk of non-Hodgkin lymphoma J Natl Cancer Inst 97 2005 587 594
17. L. Hagströmer, W. Ye, O. Nyrén, and L. Emtestam Incidence of cancer among patients with atopic dermatitis Arch Dermatol 141 2005 1123 1127
18. E.A. Holly, and P.M. Bracci Population-based study of non-Hodgkin lymphoma, histology, and medical history among human immunodeficiency virus-negative participants in San Francisco Am J Epidemiol 158 2003 316 327
19. D. Margolis, W. Bilker, S. Hennessy, C. Vittorio, J. Santanna, and B.L. Strom The risk of malignancy associated with psoriasis Arch Dermatol 137 2001 778 783
20. M. Melbye, K.E. Smedby, and T. Lehtinen Atopy and risk of non-Hodgkin lymphoma J Natl Cancer Inst 99 2007 158 166
21. M.M. Morales, J. Olsen, and P. Johansen Viral infection, atopy and mycosis fungoides: a European multicentre case-control study Eur J Cancer 39 2003 511 516
22. S. Schneeweiss, M. Doherty, and S. Zhu Topical treatments with pimecrolimus, tacrolimus and medium- to high-potency corticosteroids, and risk of lymphoma Dermatology 219 2009 7 21
23. K.C. Söderberg, L. Hagmar, J. Schwartzbaum, and M. Feychting Allergic conditions and risk of hematological malignancies in adults: a cohort study BMC Public Health 4 2004 51
24. E. Tuyp, A. Burgoyne, T. Aitchison, and R. MacKie A case-control study of possible causative factors in mycosis fungoides Arch Dermatol 123 1987 196 200
25. P. Vineis, P. Crosignani, and C. Sacerdote Haematopoietic cancer and medical history: a multicentre case control study J Epidemiol Community Health 54 2000 431 436
26. Y. Zhang, T.R. Holford, and B. Leaderer Prior medical conditions and medication use and risk of non-Hodgkin lymphoma in Connecticut United States women Cancer Causes Control 15 2004 419 428
27. M.M. Doody, M.S. Linet, and A.G. Glass Leukemia, lymphoma, and multiple myeloma following selected medical conditions Cancer Causes Control 3 1992 449 456
28. C.M. Vajdic, L. Fritschi, and A.E. Grulich Atopy, exposure to pesticides and risk of non-Hodgkin lymphoma Int J Cancer 120 2007 2271 2274
29. J. Rudant, L. Orsi, and A. Monnereau Childhood Hodgkin's lymphoma, non-Hodgkin's lymphoma and factors related to the immune system: the Escale Study (SFCE) Int J Cancer 129 2011 2236 2247
30. M. El-Zein, M.-E. Parent, K. Kâ, J. Siemiatycki, Y. St-Pierre, and M.C. Rousseau History of asthma or eczema and cancer risk among men: a population-based case-control study in Montreal, Quebec, Canada Ann Allergy Asthma Immunol 104 2010 378 384
31. C.M. Vajdic, M.O. Falster, and S. de Sanjose Atopic disease and risk of non-Hodgkin lymphoma: an InterLymph pooled analysis Cancer Res 69 2009 6482 6489
32. R.L. Hui, W. Lide, J. Chan, J. Schottinger, M. Yoshinaga, and M. Millares Association between exposure to topical tacrolimus or pimecrolimus and cancers Ann Pharmacother 43 2009 1956 1963
33. D. Thaçi, and R. Salgo Malignancy concerns of topical calcineurin inhibitors for atopic dermatitis: facts and controversies Clin Dermatol 28 2010 52 56
34. T. Miyagaki, and M. Sugaya Erythrodermic cutaneous T-cell lymphoma: how to differentiate this rare disease from atopic dermatitis J Dermatol Sci 64 2011 1 6
35. P. Tennis, J.M. Gelfand, and K.J. Rothman Evaluation of cancer risk related to atopic dermatitis and use of topical calcineurin inhibitors Br J Dermatol 165 2011 465 473
36. L.M. Morton, S.S. Wang, S.S. Devesa, P. Hartge, D.D. Weisenburger, and M.S. Linet Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001 Blood 107 2006 265 276
37. W.W. Carr Topical calcineurin inhibitors for atopic dermatitis: review and treatment recommendations Paediatr Drugs 15 2013 303 310
38. J. Ring, M. Möhrenschlager, and V. Henkel The US FDA "black box" warning for topical calcineurin inhibitors: an ongoing controversy Drug Saf 31 2008 185 198
39. N.A. Undre, F.J. Moloney, S. Ahmadi, P. Stevenson, and G.M. Murphy Skin and systemic pharmacokinetics of tacrolimus following topical application of tacrolimus ointment in adults with moderate to severe atopic dermatitis Br J Dermatol 160 2009 665 669
40. A. Rubins, R. Gutmane, N. Valdmane, P. Stevenson, C. Foster, and N. Undre Pharmacokinetics of 0.1% tacrolimus ointment after first and repeated application to adults with moderate to severe atopic dermatitis J Invest Dermatol 125 2005 68 71